Hantz O, Périgaud C, Borel C, Jamard C, Zoulim F, Trépo C, Imbach J L, Gosselin G
INSERM U. 271, Lyon, France.
Antiviral Res. 1999 Jan;40(3):179-87. doi: 10.1016/s0166-3542(98)00060-6.
The in vitro and in vivo antiviral activities of two mononucleoside phosphotriester derivatives of acyclovir (ACV) incorporating S-acyl-2-thioethyl (SATE) groups are reported using the duck model of hepatitis B (DHBV). In primary duck hepatocyte cultures, the described phosphotriesters significantly inhibited the replication of DHBV at submicromolar concentrations. They were found to be more potent than the parent nucleoside. This result was in agreement with our data concerning the anti-HBV activity of these pronucleotides in HepG2.2.15 cells (previous paper). In vivo, the studied SATE pronucleotide was also found to be more efficient than ACV in infected ducklings upon short-term oral therapy, while intraperitoneal treatment showed high anti-DHBV activity with both ACV and its SATE pronucleotide in this animal model. These findings demonstrate the potential of SATE pronucleotides of ACV as anti-HBV agents.
报道了两种含有S-酰基-2-硫代乙基(SATE)基团的阿昔洛韦(ACV)单核苷磷酸三酯衍生物在鸭乙型肝炎(DHBV)模型中的体外和体内抗病毒活性。在原代鸭肝细胞培养物中,所述磷酸三酯在亚微摩尔浓度下显著抑制DHBV的复制。发现它们比母体核苷更有效。该结果与我们之前关于这些前体核苷酸在HepG2.2.15细胞中的抗HBV活性的数据一致(前文)。在体内,经短期口服治疗后,研究的SATE前体核苷酸在感染的雏鸭中也比ACV更有效,而在该动物模型中,腹腔注射治疗显示ACV及其SATE前体核苷酸均具有高抗DHBV活性。这些发现证明了ACV的SATE前体核苷酸作为抗HBV药物的潜力。